Open AccessA 65-Year-Old Male with Primary Central Nervous System Diffuse Large B-Cell Lymphoma on Nivolumab with Oral Mucositis and Targetoid Plaques
Author(s) -
Severine Cao,
Pooyan Rohani,
Rosalynn M. Nazarian,
Daniela Kroshinsky
Publication year - 2017
Publication title -
dermatopathology
Language(s) - English
Resource type - Journals
ISSN - 2296-3529
DOI - 10.1159/000481309
Subject(s) - medicine , mucositis , nivolumab , dermatology , erythema , lymphoma , diffuse large b cell lymphoma , adverse effect , histopathology , pathology , immunotherapy , chemotherapy , cancer
The development of programmed cell death-1 (PD-1) inhibitors has greatly improved patient outcomes in the treatment of a variety of advanced malignancies. These novel immunotherapies are not without adverse effects, the most common of which are dermatologic.